{"Importance": [0], "There": [1, 162], "are": [2], "limited": [3], "efficacious": [4], "treatments": [5], "for": [6, 81, 110, 213], "Alzheimer": [7, 52, 144, 465], "disease.": [8], "Objective": [9], "To": [10], "assess": [11], "efficacy": [12], "and": [13, 28, 60, 135, 169, 235, 278, 302, 311, 347, 369, 376, 415, 426, 436, 447, 458, 467, 469, 485, 490], "adverse": [14], "events": [15], "of": [16, 175, 180, 182, 201, 400], "donanemab,": [17], "an": [18], "antibody": [19], "designed": [20], "to": [21, 75, 95, 120, 152, 203, 272, 283, 307, 316, 359, 388], "clear": [22], "brain": [23], "amyloid": [24, 59, 468], "plaque.": [25], "Design,": [26], "Setting,": [27], "Participants": [29, 88, 113], "Multicenter": [30], "(277": [31], "medical": [32], "research": [33], "centers/hospitals": [34], "in": [35, 84, 91, 114, 123, 142, 177, 261, 274, 285, 297, 328, 334, 364, 393, 405, 411, 422, 430, 443, 449, 480, 486], "8": [36], "countries),": [37], "randomized,": [38], "double-blind,": [39], "placebo-controlled,": [40], "18-month": [41], "phase": [42], "3": [43], "trial": [44], "that": [45], "enrolled": [46], "1736": [47, 219], "participants": [48, 221, 407, 432, 461], "with": [49, 58, 209, 231, 238, 309, 318, 345, 352, 374, 381, 434, 439, 462, 482], "early": [50, 463], "symptomatic": [51, 419, 464], "disease": [53, 466], "(mild": [54], "cognitive": [55], "impairment/mild": [56], "dementia)": [57], "low/medium": [61, 205, 232, 299, 366, 483, 489], "or": [62, 101, 402], "high": [63, 239, 491], "tau": [64, 206, 233, 240, 300, 367, 470, 484, 492], "pathology": [65, 234, 493], "based": [66], "on": [67], "positron": [68], "emission": [69], "tomography": [70], "imaging": [71, 398], "from": [72, 150], "June": [73], "2020": [74], "November": [76], "2021": [77], "(last": [78], "patient": [79], "visit": [80], "primary": [82, 138], "outcome": [83, 139, 174], "April": [85], "2023).": [86], "Interventions": [87], "were": [89, 118, 131, 163, 253, 453], "randomized": [90, 220], "a": [92, 124], "1:1": [93], "ratio": [94], "receive": [96, 121], "donanemab": [97, 116, 276, 310, 346, 375, 413, 435, 445, 472], "(n": [98, 103], "=": [99, 104], "860)": [100], "placebo": [102, 122, 287, 319, 353, 382, 424, 451], "876)": [105], "intravenously": [106], "every": [107], "4": [108, 437], "weeks": [109, 154, 266, 339, 479], "72": [111], "weeks.": [112], "the": [115, 172, 178, 183, 210, 245, 248, 275, 286, 298, 329, 365, 394, 412, 423, 444, 450, 487], "group": [117, 277, 288, 414, 425, 446, 452], "switched": [119], "blinded": [125], "manner": [126], "if": [127], "dose": [128], "completion": [129], "criteria": [130], "met.": [132], "Main": [133], "Outcomes": [134], "Measures": [136], "The": [137, 256], "was": [140, 267, 340], "change": [141, 176, 260, 333], "integrated": [143], "Disease": [145], "Rating": [146, 186], "Scale": [147, 187], "(iADRS)": [148], "score": [149, 189, 263, 336], "baseline": [151], "76": [153, 265, 338, 478], "(range,": [155, 190], "0-144;": [156], "lower": [157], "scores": [158, 193], "indicate": [159, 194], "greater": [160, 195], "impairment).": [161, 196], "24": [164, 249], "gated": [165, 250], "outcomes": [166], "(primary,": [167], "secondary,": [168], "exploratory),": [170], "including": [171], "secondary": [173], "sum": [179], "boxes": [181], "Clinical": [184], "Dementia": [185], "(CDR-SB)": [188], "0-18;": [191], "higher": [192], "Statistical": [197], "testing": [198, 204], "allocated": [199], "\u03b1": [200], ".04": [202], "population": [207, 215, 301, 368], "outcomes,": [208, 251], "remainder": [211], "(.01)": [212], "combined": [214, 330, 395, 488], "outcomes.": [216], "Results": [217], "Among": [218, 460], "(mean": [222], "age,": [223], "73.0": [224], "years;": [225], "996": [226], "[57.4%]": [227], "women;": [228], "1182": [229], "[68.1%]": [230], "552": [236], "[31.8%]": [237], "pathology),": [241], "1320": [242], "(76%)": [243], "completed": [244], "trial.": [246], "Of": [247], "23": [252], "statistically": [254], "significant.": [255], "least-squares": [257], "mean": [258], "(LSM)": [259], "iADRS": [262], "at": [264, 337, 477], "\u22126.02": [268], "(95%": [269, 280, 304, 313, 342, 349, 371, 378], "CI,": [270, 281, 292, 305, 314, 323, 343, 350, 357, 372, 379, 386], "\u22127.01": [271], "\u22125.03)": [273], "\u22129.27": [279], "\u221210.23": [282], "\u22128.31)": [284], "(difference,": [289, 320, 354, 383], "3.25": [290], "[95%": [291, 322, 356, 385], "1.88-4.62];": [293], "P": [294, 325, 361, 390], "&amp;amp;lt;": [295, 326, 362, 391], ".001)": [296, 327, 363, 392], "\u221210.2": [303], "\u221211.22": [306], "\u22129.16)": [308], "\u221213.1": [312], "\u221214.10": [315], "\u221212.13)": [317], "2.92": [321], "1.51-4.33];": [324], "population.": [331, 396, 494], "LSM": [332], "CDR-SB": [335], "1.20": [341], "1.00-1.41)": [344], "1.88": [348], "1.68-2.08)": [351], "\u22120.67": [355], "\u22120.95": [358, 387], "\u22120.40];": [360], "1.72": [370], "1.53-1.91)": [373], "2.42": [377], "2.24-2.60)": [380], "\u22120.7": [384], "\u22120.45];": [389], "Amyloid-related": [397], "abnormalities": [399], "edema": [401], "effusion": [403], "occurred": [404, 429], "205": [406], "(24.0%;": [408], "52": [409], "symptomatic)": [410], "18": [416], "(2.1%;": [417], "0": [418], "during": [420], "study)": [421], "infusion-related": [427], "reactions": [428], "74": [431], "(8.7%)": [433], "(0.5%)": [438], "placebo.": [440], "Three": [441], "deaths": [442], "1": [448], "considered": [454], "treatment": [455], "related.": [456], "Conclusions": [457], "Relevance": [459], "pathology,": [471], "significantly": [473], "slowed": [474], "clinical": [475], "progression": [476], "those": [481], "Trial": [495], "Registration": [496], "ClinicalTrials.gov": [497], "Identifier:": [498], "NCT04437511": [499]}